Ken Griffin Cabaletta Bio, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,900 shares of CABA stock, worth $85,239. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,900
Previous 74,000
74.46%
Holding current value
$85,239
Previous $1.26 Million
88.83%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CABA
# of Institutions
143Shares Held
49.9MCall Options Held
19.9KPut Options Held
41.5K-
Jennison Associates LLC5.55MShares$25 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.76MShares$21.5 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.88MShares$17.5 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.04MShares$13.7 Million0.04% of portfolio
-
Alkeon Capital Management LLC New York, NY2.62MShares$11.8 Million0.03% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $131M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...